The ANSM has recognized major supply problems for drugs treating type 2 diabetes due to increased global demand for this product.
The National Agency for the Safety of Medicines and Health Products (ANSM) indicated on September 23 that “high supply tensions“affect the drugs involved in the treatment of type 2 diabetes. These tensions impact two drugs in France in particular: Ozempic (semaglutide) and Trulicity (dulaglutide).
A treatment decided by the doctor
According to the ASNM, these two drugs “are indicated for the treatment of insufficiently controlled type 2 diabetes, in addition to diet and physical activity”. According to the National Institute of Health and Medical Research (INSERM), type 2 diabetes is characterized by an increasing resistance of the body to insulin, a hormone responsible for helping the absorption of glucose, resulting in increasing amounts of glucose present in the body.
Despite these supply problems, the ASNM urges patients not to change their treatment on their own: “You should not change your treatment without medical advice. Talk to your doctor who will prescribe a suitable alternative. if necessary”. If only doctors have decision-making power, the ASNM indicates that “it is not necessary to modify the usual treatment of your patient”. Recommendations have however been given to doctors so that patients at the start of treatment and in the prevention period are directed to different alternatives if their medical situation allows it.